A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 357-361

  Trudel, Dominique ^a,b   Labbé, David P ^c,d   Araya Farias, Monica ^e   Doyen, Alain ^e   Bazinet, Laurent ^e   Duchesne, Thierry ^e   Plante, Marie ^a   Grégoire, Jean ^a   Renaud, Marie Claude ^a   Bachvarov, Dimcho ^a   Têtu, Bernard ^a   Bairati, Isabelle ^a  

^a LAVAL UNIVERSITY   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

Advanced stage ovarian cancer; EGCG; Green tea; Maintenance therapy; Phase II study

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOKALEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; MOUTH ULCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; TEA; TREATMENT RESPONSE; TREMOR; UNIVERSITY HOSPITAL; VOMITING;

ADVANCED STAGE OVARIAN CANCER; EGCG; GREEN TEA; MAINTENANCE THERAPY; PHASE II STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CATECHIN; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TAXOIDS; TEA;

EID: 84886089969     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.019     Document Type: Article

References (23)

1. R.F. Ozols Treatment goals in ovarian cancer Int J Gynecol Cancer 15 Suppl. 1 May-Jun 2005 3 11
2. V. Guarneri, F. Piacentini, E. Barbieri, and P.F. Conte Achievements and unmet needs in the management of advanced ovarian cancer Gynecol Oncol 117 2 May 2010 152 158
3. L.M. Hess, N. Rong, P.O. Monahan, P. Gupta, C. Thomaskutty, and D. Matei Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis Cancer 116 22 Nov 15 2010 5251 5260
4. A.M. Oza, V. Castonguay, D. Tsoref, I. Diaz-Padilla, K. Karakasis, and H. Mackay Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective Curr Oncol 18 Suppl. 2 Oct 2011 S20 S27
5. K.W. Lee, A.M. Bode, and Z. Dong Molecular targets of phytochemicals for cancer prevention Nat Rev Cancer 11 3 Mar 2011 211 218
6. L.M. Butler, and A.H. Wu Green and black tea in relation to gynecologic cancers Mol Nutr Food Res 55 6 Jun 2011 931 940
7. D. Trudel, D.P. Labbé, I. Bairati, V. Fradet, L. Bazinet, and B. Têtu Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies Gynecol Oncol 126 3 Sep 2012 491 498
8. M.H. Ravindranath, T.S. Saravanan, C.C. Monteclaro, N. Presser, X. Ye, and S.R. Selvan Epicatechins purified from green tea (camellia sinensis) differentially suppress growth of gender-dependent human cancer cell lines Evid Based Complement Alternat Med 3 2 Jun 2006 237 247
9. A.M. Bode, and Z. Dong Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail Cancer Prev Res (Phila) 2 6 Jun 2009 514 517
10. L. Bazinet, D. Labbé, and A. Tremblay Production of green tea EGC- and EGCG-enriched fractions by a two-step extraction procedure Sep Purif Technol 56 1 2007 53 56
11. M. Zhang, A.H. Lee, C.W. Binns, and X. Xie Green tea consumption enhances survival of epithelial ovarian cancer Int J Cancer 112 3 Nov 10 2004 465 469
12. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 Mar 1989 1 10
13. S. Sundar, and K.J. O'Byrne CA-125 criteria for response evaluation in ovarian cancer Gynecol Oncol 98 3 Sep 2005 520 521
14. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, and M. Bookman consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
15. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 Jan 2009 228 247
16. S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia, and A. Corti Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study Cancer Res 66 2 Jan 15 2006 1234 1240
17. D. Labbé, M. Araya-Farias, A. Tremblay, and L. Bazinet Electromigration feasibility of green tea catechins J Membr Sci 254 1-2 2005 101 109
18. D. Labbé, B. Têtu, D. Trudel, and L. Bazinet Catechin stability of EGC- and EGCG-enriched tea drinks produced by a two-step extraction procedure Food Chem 111 1 2008 139 143
19. V.M. Montori, and G.H. Guyatt Intention-to-treat principle CMAJ 165 10 2001 Nov 13 1339 1341
20. H.H. Chow, Y. Cai, D.S. Alberts, I. Hakim, R. Dorr, and F. Shahi Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E Cancer Epidemiol Biomarkers Prev 10 1 Jan 2001 53 58
21. H.H. Chow, Y. Cai, I.A. Hakim, J.A. Crowell, F. Shahi, and C.A. Brooks Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals Clin Cancer Res 9 9 Aug 15 2003 3312 3319
22. N.M. Yunos, P. Beale, J.Q. Yu, and F. Huq Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells Anticancer Res 31 4 Apr 2011 1131 1140
23. G.C. Stuart, H. Kitchener, M. Bacon, A. duBois, M. Friedlander, and J. Ledermann Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21(4) May 2011 750 755